India Pharma Outlook Team | Friday, 26 September 2025
Pfizer Inc. is poised to highlight key advances from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025, which runs from October 17 to 21 in Berlin.
With over 45 abstracts, including 11 oral and mini oral presentations and five late-breaking presentations, Pfizer will showcase how earlier treatment with its innovative cancer medicines can provide significant survival benefits across numerous types of tumor.
Jeff Legos, Pfizer's chief oncology officer, stated that these results reflect the company's dedication to realizing the goal of accelerated access to transformative therapies.
Also Read: How PLI Scheme is Reshaping India's Drug Production Future
In one of the highlights, the trial will provide unprecedented survival data from a phase 3 trial EV-303 during a Presidential Symposium, assessing Padcev in combination with Keytruda in patients who are not eligible for cisplatin for muscle-invasive bladder cancer—with results that have the potential to shift the standard of care in this population.
The final overall survival data from the phase 3 EMBARK trial of Xtandi (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer will be shared, demonstrating a clear benefit of earlier treatment compared to standard therapy (observation). Furthermore, updated survival results from the phase 2 PHAROS trial of the combination of Braftovi (encorafenib) plus Mektovi (binimetinib) in patients with BRAF V600E-mutant NSCLC will further support the potential of this targeted combination.
With a portfolio spanning small molecules, antibody-drug conjugates, and multispecific antibodies, Pfizer Oncology continues to advance therapies in breast, lung, genitourinary, and hematologic cancers, marking a new era of innovation in cancer care.
